A Phase 1b, Multicenter, Two-Part, Open-Label Study of DS-8201a, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination With Nivolumab, an Anti-PD-1 Antibody, for Subjects With HER2-expressing Advanced Breast and Urothelial Cancer

Conditions

Other Urinary | Breast | Urinary Bladder

Phase IB

What is the purpose of this trial?

This is a study of DS-8201a, which is an experimental drug not approved yet by the FDA.

Participants will receive this study drug along with a cancer drug that is already being used, called nivolumab.

The study will be done in two parts:

  • Part 1 is to identify the recommended dose to use for treatment.
  • Part 2 is to find out how well the combination works, and how safe and tolerable it is.
  • Trial with
    Daiichi Sankyo
  • Start Date
    04/25/2019
  • End Date
    09/29/2020

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Matthew Piscatelli

  • Last Updated
    04/29/2019
  • Study HIC
    #2000023642